Swollen Joint News and Research

RSS
Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Mallinckrodt Study Shows Acthar® Reduces Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus

Hispanic mortality paradox found in RA patients

Hispanic mortality paradox found in RA patients

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Phase 3 study shows STELARA inhibits structural damage in patients with active psoriatic arthritis

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Ustekinumab doses improve signs and symptoms of PsA with favourable safety profiles

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

New study shows treatment with brodalumab demonstrates clinical response in subjects with PsA

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

Researchers discover new gene for susceptibility to Alzheimer's disease

Researchers discover new gene for susceptibility to Alzheimer's disease

Study quantifies discrepancies between physicians and patients with rheumatoid arthritis

Study quantifies discrepancies between physicians and patients with rheumatoid arthritis

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Discrepancies between patients and physicians' views of RA disease activity

Discrepancies between patients and physicians' views of RA disease activity

Rheumatoid arthritis patients and their doctors differ on perception of disease activity

Rheumatoid arthritis patients and their doctors differ on perception of disease activity

Simple blood test may help physicians track progression of RA disease activity

Simple blood test may help physicians track progression of RA disease activity

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

STELARA effectively reduces signs and symptoms of active psoriatic arthritis

SC formulation of Genentech’s ACTEMRA shows promise against RA

SC formulation of Genentech’s ACTEMRA shows promise against RA

New ACR classification criteria for polymyalgia rheumatica

New ACR classification criteria for polymyalgia rheumatica

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting

UCB to sponsor several key sets of Cimzia data on RA at ACR 2011 meeting